Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Palo Alto, California 94304


Purpose:

The purpose of this study is to determine whether fresh garlic can positively affect cholesterol in adults with moderately high cholesterol levels. This study will also determine whether the same effects can be found for two main types of garlic supplements: a dried powdered garlic (designed to yield the same effect as fresh garlic) and an aged garlic extract preparation.


Study summary:

Garlic supplements are the most consumed herbal products in the United States. The most common health claim made for garlic supplements is cholesterol lowering activity. This claim has not been supported by recent clinical trials and meta-analyses. However, data suggest that it is not necessarily the garlic that has been ineffective, but rather the particular garlic preparations being used. To date, the predominant type of garlic preparation used in these clinical trials has been dried garlic powders. A few clinical trials have reported beneficial lipid effects using an aged garlic extract, and only a small number of inconclusive uncontrolled trials have used fresh garlic. A rigorous trial directly comparing different types of garlic preparations for their effects on serum lipids is needed. Adults with moderately elevated low density lipoprotein cholesterol (LDL-C) will be randomized to one of four groups for 6 months: fresh garlic, dried powdered garlic tablets, aged garlic extract tablets, or placebo control. The fresh garlic will be provided to patients with "study sandwiches"; all other groups will receive the same study sandwiches without the garlic. All patients will take daily study tablets, but the tablet assignment will be double-blind. Patients will pick up study sandwiches twice a week and study tablets once every 2 weeks for 28 weeks. Blood samples will be taken once a month, with additional blood draws at the start and end of the study.


Criteria:

Inclusion Criteria: - LDL-C 130-190 mg/dL (fasting single sample) - BMI (body mass index) 19-30 kg/m2 (42-66 lb/m2) - Weight stable for last 2 months - Not actively on a weight loss plan - Ethnicity representative of local population - No plans to move from the area over the next 9 months Exclusion Criteria: - Pregnant, lactating, within 6 months postpartum, or planning to become pregnant in the next year - Diabetes (type I or II) or history of gestational diabetes - Heart disease - Active neoplasms - Renal or liver disease - Hyperthyroidism or hypothyroidism - Lipid lowering medications (known to affect lipid metabolism, platelet function, or antioxidant status) - Blood pressure medications - Excessive alcohol intake (self reported, more than 3 drinks/day) - Currently under psychiatric care or severely clinically depressed


NCT ID:

NCT00056511


Primary Contact:

Principal Investigator
Christopher D. Gardner, Ph.D.
Stanford Center for Research in Disease Prevention


Backup Contact:

N/A


Location Contact:

Palo Alto, California 94304
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 10, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.